A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone
Open Access
- 13 September 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 604, 217245
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- The University of Texas MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
- National Cancer Institute Division of Cancer Prevention
This publication has 27 references indexed in Scilit:
- Early screening and diagnosis strategies of pancreatic cancer: a comprehensive reviewCancer Communications, 2021
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionNature Genetics, 2020
- Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset DiabetesGastroenterology, 2018
- Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term SurveillanceGastroenterology, 2018
- A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter StudyAmerican Journal of Gastroenterology, 2017
- Glycans Related to the CA19-9 Antigen Are Increased in Distinct Subsets of Pancreatic Cancers and Improve Diagnostic Accuracy Over CA19-9Cellular and Molecular Gastroenterology and Hepatology, 2016
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007